Mohammed J. Rahman, MD, oncologist, University of Pittsburgh Medical Center, discusses the roles of pertuzumab and neratinib in patients with HER2-positive breast cancer.
Mohammed Rahman, MD
Advertisement
Articles by Mohammed Rahman, MD
Advertisement
Latest Updated Articles
Dr. Rahman on Pertuzumab and Neratinib in HER2+ Breast CancerPublished: November 7th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5